NO20080829L - Sammensetninger og metoder for kontroll av angiogenese med cupredoxiner - Google Patents

Sammensetninger og metoder for kontroll av angiogenese med cupredoxiner

Info

Publication number
NO20080829L
NO20080829L NO20080829A NO20080829A NO20080829L NO 20080829 L NO20080829 L NO 20080829L NO 20080829 A NO20080829 A NO 20080829A NO 20080829 A NO20080829 A NO 20080829A NO 20080829 L NO20080829 L NO 20080829L
Authority
NO
Norway
Prior art keywords
compositions
cupredoxins
angiogenesis
methods
peptides
Prior art date
Application number
NO20080829A
Other languages
English (en)
Inventor
Ananda Chakrabarty
Tapas Das Gupta
Rajeshwari Mehta
Brad Taylor
Tohru Yamada
Craig Beattie
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/244,105 external-priority patent/US7691383B2/en
Priority claimed from US11/436,592 external-priority patent/US7381701B2/en
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of NO20080829L publication Critical patent/NO20080829L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SAMMENDRAG Den foreliggende oppfinnelse vedrører sammensetninger omfattende cupredoxiner, og deres anvendelse for å inhibere angiogenese i mammalske celler, vev, og dyr, og særskilt angiogenesen som medfølger tumorutvikling og særskilt i mennesker. Spesifikt vedrører den foreliggende oppfinnelse sammensetninger omfattende cupredoxinet(ene), og eller peptider som er varianter, derivater eller strukturelle ekvivalenter av cupredoxiner, som bibeholder evnen til å inhibere angiogenese i mammalske celler, vev eller dyr. Disse sammensetningene kan være peptider eller farmasøytiske sammensetninger, blant andre. Sammensetningene av oppfinnelsen kan brukes for å behandle en hvilken som helst patologisk tilstand som har som et symptom eller årsak, upassende angiogenese, og særskilt upassende angiogenese relatert til tumorutvikling.
NO20080829A 2005-07-19 2008-02-15 Sammensetninger og metoder for kontroll av angiogenese med cupredoxiner NO20080829L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70029705P 2005-07-19 2005-07-19
US11/244,105 US7691383B2 (en) 2004-10-07 2005-10-06 Cupredoxin derived transport agents and methods of use thereof
US76474906P 2006-02-03 2006-02-03
US11/436,592 US7381701B2 (en) 2001-02-15 2006-05-19 Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
PCT/US2006/027940 WO2007024368A2 (en) 2005-07-19 2006-07-19 Compositions and methods to control angiogenesis with cupredoxins

Publications (1)

Publication Number Publication Date
NO20080829L true NO20080829L (no) 2008-04-02

Family

ID=37772089

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080829A NO20080829L (no) 2005-07-19 2008-02-15 Sammensetninger og metoder for kontroll av angiogenese med cupredoxiner

Country Status (10)

Country Link
EP (1) EP1904081A4 (no)
JP (1) JP2009502797A (no)
KR (1) KR20080034905A (no)
AU (1) AU2006284490A1 (no)
BR (1) BRPI0615555A2 (no)
CA (1) CA2615560A1 (no)
IL (1) IL188691A0 (no)
MX (1) MX2008000993A (no)
NO (1) NO20080829L (no)
WO (1) WO2007024368A2 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158574B2 (en) * 2004-10-07 2012-04-17 Cdg Therapeutics, Inc. Compositions and methods to prevent cancer with cupredoxins
AU2007296429A1 (en) * 2006-09-14 2008-03-20 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US8017749B2 (en) 2006-12-04 2011-09-13 The Board Of Trustees Of The University Of Illinois Compositions and methods to treat cancer with cupredoxins and CpG rich DNA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491394B2 (en) * 2001-02-15 2009-02-17 The Board Of Trustees Of The University Of Illinois Cytotoxic factors for modulating cell death
AU2005327535A1 (en) * 2004-10-07 2006-08-24 Ananda Chakrabarty Cupredoxin derived transport agents and methods of use thereof
KR20080019615A (ko) * 2005-05-20 2008-03-04 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 시토크롬으로 말라리아를 치료하기 위한조성물과 방법
CA2608398A1 (en) * 2005-05-20 2006-11-30 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating hiv infection with cupredoxin and cytochrome c
EP1888106A4 (en) * 2005-05-20 2009-01-14 Univ Illinois COMPOSITIONS AND METHODS FOR TREATING EPHRIN SIGNALING WITH CUPREDOXINES

Also Published As

Publication number Publication date
EP1904081A4 (en) 2008-12-03
IL188691A0 (en) 2008-08-07
AU2006284490A1 (en) 2007-03-01
JP2009502797A (ja) 2009-01-29
WO2007024368A3 (en) 2007-10-11
AU2006284490A8 (en) 2008-02-28
CA2615560A1 (en) 2007-03-01
MX2008000993A (es) 2008-03-19
WO2007024368A2 (en) 2007-03-01
BRPI0615555A2 (pt) 2009-07-14
EP1904081A2 (en) 2008-04-02
KR20080034905A (ko) 2008-04-22

Similar Documents

Publication Publication Date Title
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EA200870019A1 (ru) Лактамовые соединения и способы их применения
NO20064584L (no) Tetrahydropyridoindolderivater
NO20091326L (no) Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase
NO20083572L (no) Tiazolforbindelser som proteinkinase-B (PKB)-inhibitorer
NO20081354L (no) Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav
EA200700058A1 (ru) Соединения, композиции и способы их использования
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20083324L (no) Multisykliske aminosyrederivater og anvendelse derav
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
NO20076515L (no) Hydantoinforbindelser
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
HK1134283A1 (en) Arylsulfonamide compounds
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
NO20054769L (no) Substituerte fenylalkansyrer
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20084435L (no) C-MET proteinkinaseinhibitorer
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
EA201001558A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ anr NOX-ИНГИБИТОРЫ ДЛЯ ПОДАВЛЕНИЯ АКТИВНЫХ ФОРМ КИСЛОРОДА
WO2007078839A3 (en) Compounds, compositions and methods
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application